Modafinil

證據等級: L5

預測適應症: 1 個

Modafinil: From Excessive Sleepiness (Narcolepsy/Sleep Disorders) to Insomnia

One-Sentence Summary

Modafinil is a wake-promoting agent approved in multiple markets (US FDA, EU) for narcolepsy, obstructive sleep apnea, and shift work sleep disorder. The TxGNN model predicts it may be effective for Insomnia, with 29 clinical trials and 19 publications identified — however, the mechanistic rationale contains a fundamental paradox that warrants careful interpretation. Evidence level is currently L3, and most clinical data involves the related compound armodafinil or secondary endpoints rather than primary insomnia treatment.

Quick Overview

Item	Content
Original Indication	Narcolepsy, obstructive sleep apnea, shift work sleep disorder (globally approved; no India registration found)
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.85%
Evidence Level	L3
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Modafinil promotes wakefulness primarily by inhibiting the dopamine transporter (DAT) and enhancing histaminergic and orexin (hypocretin) neurotransmission, while also exerting indirect effects on the norepinephrine system. These mechanisms suppress non-REM sleep and sustain alertness — which is why it is effective for conditions of pathological daytime sleepiness.

Here lies the central paradox: administering a potent wake-promoting agent to patients with difficulty falling or staying asleep is mechanistically counterintuitive. In principle, reinforcing wakefulness signals in an already-hyperaroused insomnia patient would be expected to worsen sleep onset, not improve it. The TxGNN model’s high prediction score likely reflects the proximity of insomnia and sleep-wake dysregulation in the knowledge graph — they are closely connected disease nodes — rather than a direct therapeutic alignment.

There is, however, one indirect mechanistic pathway worth noting. In specific patient subgroups (oncology patients, those with neurodegenerative disease), excessive daytime fatigue disrupts circadian rhythm, which then destabilises nocturnal sleep architecture. In these settings, improving daytime wakefulness with modafinil may indirectly normalise the circadian pattern and reduce secondary insomnia — a hypothesis referred to as “circadian rhythm normalisation.” This indirect route has biological plausibility but requires dedicated clinical validation. Critically, it does not translate directly to primary insomnia without comorbidity.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00124384	Phase 4	Completed	40	Most directly relevant. Examines modafinil (alone or combined with CBT-I) in patients with primary insomnia — assessing both daytime functioning and sleep severity. Small sample limits conclusions.
NCT01011218	Phase 2	Completed	70	Armodafinil 150 mg/day combined with CBT-I in breast cancer patients with insomnia. Direct insomnia endpoint, but limited to cancer-related insomnia subgroup.
NCT01091974	Phase 2	Completed	138	Four-arm RCT of CBT-I ± armodafinil for insomnia and fatigue in breast cancer survivors post-chemotherapy. Armodafinil, not modafinil; specific oncology population.
NCT01019187	Phase 2	Completed	226	Armodafinil ± CBT-I for insomnia and fatigue in cancer survivors after chemotherapy. Larger sample; same caveats as above.
NCT02552303	N/A	Completed	39	Armodafinil and/or CBT-I for insomnia comorbid with sleep-disordered breathing (OSA). Insomnia directly targeted, but in a comorbid OSA population.
NCT06404086	Phase 2	Completed	830	RECOVER-SLEEP platform trial for sleep disturbances in Long COVID (PASC). Multiple interventions; modafinil may be one arm. Signals emerging from a real-world affected population.
NCT01965925	Phase 4	Completed	18	Modafinil for circadian and cognitive dysfunction in stable bipolar disorder. Sleep quality is a secondary outcome; very small sample.
NCT00626210	Phase 4	Terminated	2	Modafinil for sleep/wake disturbances in older adults. Terminated early due to poor recruitment (n=2); no usable data.
NCT07295834	Phase 2	Not Yet Recruiting	70	Modafinil vs. placebo for severe fatigue in inflammatory bowel disease (IBD). Future trial; no data available yet, but confirms ongoing research interest.
NCT01305408	Phase 3	Completed	399	Armodafinil 150 mg/day as adjunct therapy in bipolar I major depression. Large, well-powered trial; sleep not the primary endpoint, and armodafinil differs from modafinil.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
18729534	2008	Evidence-Based Review	Drugs	Comprehensive review of modafinil’s approved and investigational uses; covers RCTs across sleepiness, fatigue, and cognitive domains. Anchor reference for modafinil’s evidence base.
24312590	2013	Systematic Review & Meta-analysis	PLOS ONE	Meta-analysis of modafinil for fatigue and excessive daytime sleepiness in neurological disorders (MS, PD, TBI). Inconsistent results across conditions; supports efficacy for EDS, not primary insomnia.
27010071	2016	Systematic Review	Parkinsonism & Related Disorders	Systematic review of pharmacological interventions for daytime sleepiness and sleep disorders in PD. Contextualises modafinil’s role within the sleep-wake spectrum.
22021174	2011	EBM Review (MDS)	Movement Disorders	Movement Disorder Society EBM review of non-motor PD treatments, including sleep. High-authority reference for understanding modafinil’s role in sleep-adjacent conditions.
39535843	2024	Review	Expert Opinion on Pharmacotherapy	Current management of sleep disturbances in PD, covering both pharmacological and non-pharmacological options. Most recent entry; highlights ongoing gaps in evidence.
18219235	2008	RCT	Journal of Head Trauma Rehabilitation	Randomised trial of modafinil for fatigue and excessive daytime sleepiness in chronic traumatic brain injury. Supports modafinil’s role in secondary sleep disruption due to neurological injury.
20082966	2009	Review	Parkinsonism & Related Disorders	Review of excessive daytime sleepiness in PD; discusses modafinil alongside narcolepsy-like REM intrusion patterns.
30214155	2018	Drug Profile Review	Drug Design, Development and Therapy	Profile of pitolisant for narcolepsy; places modafinil in the competitive landscape of wake-promoting agents. Useful for positioning.
18805301	2008	Review	Revue Neurologique	Review of narcolepsy with cataplexy; modafinil cited as first-line treatment for EDS. Clarifies where modafinil is established versus speculative.
17060310	2006	Case Series	American Journal of Hospice & Palliative Care	Modafinil reduces fatigue in Charcot-Marie-Tooth disease type 1A. Illustrates modafinil’s off-label use for secondary fatigue/sleepiness; low evidence tier but mechanistically informative.

India Market Information

Modafinil currently has no registered products in India. No license data is available for tabulation. The drug is approved in other major markets (US FDA, EU EMA) for narcolepsy, obstructive sleep apnea, and shift work sleep disorder, but has not obtained India marketing authorisation as of the data cutoff (2026-04-04).

Safety Considerations

Drug Interactions (249 total interactions identified):

Key interactions to monitor if modafinil use is considered:

Interacting Drug	Interaction Level	Clinical Relevance
Dexamethasone	Moderate	CYP3A4 induction may reduce dexamethasone efficacy
Esomeprazole	Moderate	Potential altered PPI metabolism via CYP2C19
Omeprazole	Moderate	Same CYP2C19 pathway concern as esomeprazole
Rabeprazole	Moderate	Similar proton pump inhibitor interaction
Eliglustat	Moderate	Narrow therapeutic index drug; CYP interaction risk
Linagliptin	Moderate	Possible reduced DPP-4 inhibitor exposure
Cisapride	Moderate	QT prolongation risk when combined
Clarithromycin	Minor	CYP3A4 inhibitor may increase modafinil exposure
Hydrocortisone	Minor	Mild CYP induction effect
Pioglitazone	Minor	Modafinil may reduce thiazolidinedione levels

The total interaction count of 249 indicates a wide drug interaction profile, primarily driven by modafinil’s CYP3A4/2C19 induction effects. Formal warnings and contraindications from the package insert are not available in the current dataset — refer to the originator label (Provigil/Nuvigil) for comprehensive safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model assigns a near-perfect score to modafinil for insomnia, but this reflects topological proximity in the knowledge graph rather than a mechanistically coherent treatment hypothesis. Modafinil’s core pharmacology — promoting wakefulness via DAT inhibition and orexin enhancement — is directly opposed to the goal of treating insomnia. The only Phase 4 trial in primary insomnia patients (NCT00124384, n=40) is too small to be conclusive, and the remaining clinical evidence predominantly involves armodafinil (a related but distinct compound) in comorbid or secondary insomnia contexts. The drug is also not registered in India, adding a regulatory hurdle.

To proceed to the next decision stage, the following is needed:

MOA documentation: Retrieve complete DrugBank mechanistic data to formally characterise the wake-promoting pathway and assess whether any aspect plausibly targets hyperarousal insomnia
Full review of NCT00124384: Obtain the complete results of the primary insomnia Phase 4 trial — specifically whether modafinil worsened, improved, or had no effect on sleep onset/maintenance measures
Subgroup clarification: Define the target patient population — if the indication is “secondary insomnia in cancer or neurodegenerative disease patients with daytime fatigue,” the evidence base and mechanistic rationale are substantially stronger than for primary insomnia
DDI safety screening: With 249 interactions documented, a structured safety screen against the intended co-medication profile is required before any clinical advance
India regulatory pathway assessment: Clarify whether a new drug application or import license would be required given current non-marketed status
Direct RCT evidence: Commission or identify a prospective trial specifically in the target insomnia subpopulation before any Phase 2/3 investment is justified

⚠️ Research Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any clinical application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.